These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25402633)

  • 1. RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification.
    Ćwiek P; Leni Z; Salm F; Dimitrova V; Styp-Rekowska B; Chiriano G; Carroll M; Höland K; Djonov V; Scapozza L; Guiry P; Arcaro A
    Oncotarget; 2015 Jan; 6(1):116-29. PubMed ID: 25402633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.
    Wang F; Remke M; Bhat K; Wong ET; Zhou S; Ramaswamy V; Dubuc A; Fonkem E; Salem S; Zhang H; Hsieh TC; O'Rourke ST; Wu L; Li DW; Hawkins C; Kohane IS; Wu JM; Wu M; Taylor MD; Wu E
    Oncotarget; 2015 Feb; 6(5):2709-24. PubMed ID: 25576913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma.
    Fiaschetti G; Schroeder C; Castelletti D; Arcaro A; Westermann F; Baumgartner M; Shalaby T; Grotzer MA
    Acta Neuropathol Commun; 2014 Apr; 2():39. PubMed ID: 24708907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
    BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
    Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
    Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
    Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
    Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.
    Salm F; Dimitrova V; von Bueren AO; Ćwiek P; Rehrauer H; Djonov V; Anderle P; Arcaro A
    PLoS One; 2015; 10(4):e0123958. PubMed ID: 25915540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCTAIRE1/CDK16/PCTK1 is overexpressed in cutaneous squamous cell carcinoma and regulates p27 stability and cell cycle.
    Yanagi T; Hata H; Mizuno E; Kitamura S; Imafuku K; Nakazato S; Wang L; Nishihara H; Tanaka S; Shimizu H
    J Dermatol Sci; 2017 May; 86(2):149-157. PubMed ID: 28274513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma.
    Li Y; Guessous F; Johnson EB; Eberhart CG; Li XN; Shu Q; Fan S; Lal B; Laterra J; Schiff D; Abounader R
    Lab Invest; 2008 Feb; 88(2):98-111. PubMed ID: 18059365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
    Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
    Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells.
    von Bueren AO; Shalaby T; Oehler-Jänne C; Arnold L; Stearns D; Eberhart CG; Arcaro A; Pruschy M; Grotzer MA
    BMC Cancer; 2009 Jan; 9():10. PubMed ID: 19134217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
    Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling medulloblastoma in vivo and with human cerebellar organoids.
    Ballabio C; Anderle M; Gianesello M; Lago C; Miele E; Cardano M; Aiello G; Piazza S; Caron D; Gianno F; Ciolfi A; Pedace L; Mastronuzzi A; Tartaglia M; Locatelli F; Ferretti E; Giangaspero F; Tiberi L
    Nat Commun; 2020 Jan; 11(1):583. PubMed ID: 31996670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
    Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
    Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma.
    Lau KM; Chan QK; Pang JC; Ma FM; Li KK; Yeung WW; Cheng AS; Feng H; Chung NY; Li HM; Zhou L; Wang Y; Mao Y; Ng HK
    Acta Neuropathol; 2012 Apr; 123(4):553-71. PubMed ID: 22249617
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
    Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
    Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
    Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
    Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
    Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma.
    Fiaschetti G; Castelletti D; Zoller S; Schramm A; Schroeder C; Nagaishi M; Stearns D; Mittelbronn M; Eggert A; Westermann F; Ohgaki H; Shalaby T; Pruschy M; Arcaro A; Grotzer MA
    Oncogene; 2011 Jun; 30(25):2823-35. PubMed ID: 21317922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth.
    Sengupta S; Weeraratne SD; Sun H; Phallen J; Rallapalli SK; Teider N; Kosaras B; Amani V; Pierre-Francois J; Tang Y; Nguyen B; Yu F; Schubert S; Balansay B; Mathios D; Lechpammer M; Archer TC; Tran P; Reimer RJ; Cook JM; Lim M; Jensen FE; Pomeroy SL; Cho YJ
    Acta Neuropathol; 2014 Apr; 127(4):593-603. PubMed ID: 24196163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.